SynthesisFrontiers in pharmacology2026
Research trends of nanotechnology in coronary heart disease: a bibliometric analysis from 2012 to 2025.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary heart disease (CHD) remains a leading cause of mortality worldwide, with conventional therapeutic strategies limited by non-specific targeting, low bioavailability, and systemic off-target effects. Nanomaterials, leveraging their unique physicochemical properties, have shown immense potential in CHD diagnosis and therapy. However, the global research landscape, knowledge structure, and thematic evolution of nanomaterials in CHD have not been systematically evaluated. Methods: Relevant publications from 2012 to 2025 were retrieved from the Web of Science Core Collection and Scopus databases. Bibliometric and visualization analyses were performed using CiteSpace, VOSviewer, and Scimago Graphica. The study evaluated publication trends, international and institutional collaboration networks, co-occurrence patterns, citation characteristics, and emerging research themes through keyword clustering and burst detection. Results: A total of 2,709 publications were included, demonstrating a continuous increase in research activity during the study period. China and the United States were the leading contributors in publication output and international collaboration. Major institutional contributors included Harvard University, Massachusetts General Hospital, and the Chinese Academy of Sciences. Keyword co-occurrence and burst analyses identified several major research directions, including nanobiosensing, molecular imaging, targeted nanoparticle delivery, and regenerative medicine. Among these evolving themes, immune-inflammatory mechanisms, macrophage/monocyte regulation, oxidative stress, and microenvironmental modulation have emerged as increasingly prominent research directions in nanotechnology-based CHD investigation. Conclusion: This bibliometric analysis provides an overview of the global development and knowledge evolution of nanotechnology research in CHD from 2012 to 2025. The findings indicate that immune-inflammatory mechanisms represent an emerging research theme within the broader landscape of cardiovascular nanotechnology. The growing attention toward immune modulation and disease-specific microenvironment regulation identified in this study may represent important directions for future translational research in cardiovascular nanotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.